hackint0sh/New-Dataset huggingface dataset:
* To determine the association between timing of appearance of obstructive sleep apnea symptoms and initiation of smoking. conditions: Obstructive Sleep Apnea conditions: Vasovagal Syncope conditions: Smoking conditions: Acanthosis Nigricans studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: In-lab polysomnography name: Continuous positive airway pressure measure: Clinical association between obstructive sleep apnea and presence of facial pigmentation measure: Clinical association between obstructive sleep apnea and severity of facial pigmentation measure: Relation between obstructive sleep apnea and vasovagal symptoms measure: Relation between obstructive sleep apnea and resulting smoking tendency due to vasovagal symptoms measure: Relation between obstructive sleep apnea and the effect of treatment on facial discolouration measure: Relation between obstructive sleep apnea and the effect of treatment on vasovagal symptoms measure: Relation between obstructive sleep apnea and the effect of treatment on smoking habits sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The University of Jordan status: RECRUITING city: Amman zip: 11942 country: Jordan name: Asma Btoosh, MD role: CONTACT phone: 00962797684137 email: asmaalbtoosh@gmail.com name: Rand M Zaqqa role: PRINCIPAL_INVESTIGATOR name: Ayah M Zaqqa, MD role: PRINCIPAL_INVESTIGATOR name: Maisa Mansoor, MD role: PRINCIPAL_INVESTIGATOR name: Asma Btoosh, MD role: PRINCIPAL_INVESTIGATOR name: Salah Salah role: SUB_INVESTIGATOR lat: 31.95522 lon: 35.94503 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2024-03-07 uploadDate: 2024-03-07T14:03 filename: Prot_000.pdf size: 82683 hasResults: False
nctId: NCT06331806 id: IEO 398 briefTitle: Myocardial Fibrosis Identification in Patients With Anthracycline-induced Cardiotoxicity overallStatus: RECRUITING date: 2018-02-22 date: 2024-12-31 date: 2024-12-31 date: 2024-03-26 date: 2024-03-26 name: European Institute of Oncology class: OTHER briefSummary: This is an interventional study for patients who had developed Anthracycline-Induced Cardiotoxicity (AIC) during or after anthracycline-containing therapy, referred to the Cardioncology Unit for heart failure treatment conditions: Cardiomyopathy Due to Drug studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 100 type: ESTIMATED name: Evaluation of myocardial fibrosis measure: Evaluation of blood levels of Suppression Of Tumorigenicity 2 (ST2) measure: Evaluation of blood levels of Galectin-3 (Gal-3) measure: Evaluation of Enhanced Liver Fibrosis score (ELF) measure: Evaluation of CMR imaging marker of fibrosis measure: Evaluation of response to heart failure treatment measure: Evaluation of levels of Troponin I (TnI) and B-type Natriuretic Peptide (BNP) measure: Evaluation of levels of cytochrome C sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: European Institute of Oncology status: RECRUITING city: Milan country: Italy name: Daniela Cardinale, MD role: CONTACT email: daniela.cardinale@ieo.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06331793 id: IEO 1849 briefTitle: Pulsed Electromagnetic Fields for Analgesia Post Mastectomy acronym: Algocare overallStatus: RECRUITING date: 2023-05-09 date: 2024-12-31 date: 2024-12-31 date: 2024-03-26 date: 2024-03-26 name: European Institute of Oncology class: OTHER briefSummary: Study aim is to test AlgoCare, a device that uses the technology PEMF (Pulsed ElectroMagnetic Fields) for the treatment of postoperative pain in oncological breast surgery, in order to demonstrate that the use of Algocare in the postoperative period allows for a reduction in pain intensity in terms of Numerical Rating Scale (NRS) score and use of analgesic drugs. conditions: Female Breast Cancer conditions: Post Operative Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomization 1:1 primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Double blind whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 160 type: ESTIMATED name: Active AlgoCare name: Non-active AlgoCare measure: Pain intensity measure: Need for analgesic drugs measure: Patient reported pain characteristics measure: Number of participants with other symptoms measure: Need for other drugs measure: Wound healing timing sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: European Institute of Oncology status: RECRUITING city: Milan zip: 20141 country: Italy name: Daniele Sances, MD role: CONTACT phone: +390257489618 email: daniele.sances@ieo.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06331780 id: WS10370 id: 2023-A02153-42 type: OTHER domain: ANSM (France) briefTitle: Refractive Status and Accommodation Response Under Different Experimental Conditions. overallStatus: RECRUITING date: 2024-02-22 date: 2024-07-31 date: 2024-12-31 date: 2024-03-26 date: 2024-03-26 name: Essilor International class: INDUSTRY briefSummary: Eye Care Professionals (ECPs) massively use auto-refractors during the patient journey to measure the objective refractive error: starting point of the subjective eye refraction. These devices provide objective information about the refractive and accommodative state of the eye, useful for the ECP to perform a complete eyesight test. Auto-refractor data for the distance vision are repeatable and accurate but near vision information are not enough reliable to build an accurate near vision routine exam. Previous internal studies, with auto refractors currently on the market, have shown that, during accommodation measurements, a large proportion of participants had a lower accommodative response than expected. conditions: Accommodation Disorder conditions: Accommodative Fatigue conditions: Accommodative Inertia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SCREENING masking: NONE count: 55 type: ESTIMATED name: Visual acuity name: Objective refraction name: Objective monocular accommodation amplitude measurement name: Subjective monocular accommodation amplitude measurement with the "Push-Up" method name: Subjective monocular accommodation facility measurement with the "Rock" method: name: CISS Questionnaire name: Difficulty assessment questionnaire name: Subjective evaluation questionnaire measure: Accommodative response measured with closed-field aberrometer with different target displacement methods measure: Accommodative response measured with closed-field aberrometer with different displayed targets measure: Objective refraction measured with closed-field aberrometer and two camera exposure times sex: ALL minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Essilor International - Ci&T 2 status: RECRUITING city: Créteil zip: 94000 country: France name: Jérôme Gillet role: CONTACT phone: +33 (0)1 49 80 63 40 email: gilletj@essilor.fr lat: 48.78333 lon: 2.46667 hasResults: False
nctId: NCT06331767 id: 2024P000654 briefTitle: Development of a Multilevel HIV Prevention Intervention for the Emergency Department acronym: mSYNC overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2029-04 date: 2029-04 date: 2024-03-26 date: 2024-03-26 name: Brigham and Women's Hospital class: OTHER briefSummary: The goal of this clinical trial is to pilot test a psychosocial-behavioral mobile health (mHealth) human immunodeficiency virus (HIV) prevention intervention in people who use drugs presenting to the emergency department (ED). The main question the study aims to answer is: is the intervention acceptable and appropriate? Participants will use the mHealth app while waiting in the ED and also at home for 90 days. Participants will be asked to complete surveys at baseline, before leaving the ED, and at 30-, 60-, and 90-day follow up visits. conditions: HIV conditions: Drug Use conditions: Mental Health conditions: Psychological Distress conditions: Social Marginalization conditions: Problems With Access to Health Care studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 100 type: ESTIMATED name: mSYNC measure: Acceptability measure: Acceptability measure: Acceptability measure: Appropriateness measure: Appropriateness measure: Appropriateness sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06331754 id: ATMANHEALTH001 briefTitle: Technology-Enabled Remote Hypertension Management To Advance Health Equity overallStatus: NOT_YET_RECRUITING date: 2024-03-18 date: 2025-09-17 date: 2026-03-17 date: 2024-03-26 date: 2024-03-26 name: Atman Health, Inc class: INDUSTRY briefSummary: The primary objective of this study is to reliably estimate the difference in blood pressure control of a technology-enabled solution for blood pressure (BP) management over usual care. The study will also assess patient and provider satisfaction with the solution. Finally, the investigators will estimate the economic impact of the intervention in terms of resource utilization. conditions: Hypertension studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: non-blinded pragmatic cluster-randomized controlled trial with a single intervention primaryPurpose: TREATMENT masking: NONE count: 1500 type: ESTIMATED name: Technology-enabled blood pressure management measure: Difference in SBP change measure: HEDIS proportion measure: Difference in DBP change measure: Home measured change in SBP and DBP measure: Patient satisfaction measure: Provider satisfaction measure: Mean time required per patient for provider measure: Mean time required per patient for navigator measure: Proportion of patients measuring blood pressure at directed frequency measure: Resource utilization sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06331741 id: 0403 briefTitle: Collagen for Treatment of Musculoskeletal Injuries overallStatus: RECRUITING date: 2024-03-01 date: 2025-03-01 date: 2026-03-01 date: 2024-03-26 date: 2024-03-26 name: I.M. Sechenov First Moscow State Medical University class: OTHER briefSummary: The purpose of the study:
Evaluation of the clinical efficacy and safety of the use of collagen matrix/membrane in the surgical treatment of the consequences of injuries and diseases of the musculoskeletal system (anterior cruciate ligament tears, rigid first toe) by using IKDC, KOOS, ACLOAS, VAS, AOFAS, SF-36 scales conditions: Anterior Cruciate Ligament Injuries conditions: Hallux Rigidus studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Main group for ACL: 5 patients with ACL injury, who undergo ACL reconstruction with collagen membrane augmentation; Reference group for ACL: 5 patients with ACL injury, who undergo ACL reconstruction without collagen membrane augmentation; Main group for HR (Hallux Rigidus): 5 patients with Hallux Rigidus, who undergo resection arthroplasty with introduction of collagen membrane Reference group: none primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 15 type: ESTIMATED name: Anterior cruciate ligament reconstruction, using graft, augmented with collagen membrane name: Anterior cruciate ligament reconstruction, using graft, not augmented with collagen membrane (control group) name: Resection arthroplasty of the first metatarsophalangeal joint with the introduction of a collagen membrane into the joint cavity measure: The International Knee Documentation Committee score measure: The Knee injury and Osteoarthritis Outcome Score measure: Modified Lysholm scale measure: Anterior Cruciate Ligament OsteoArthritis Score measure: American Orthopaedic Foot and Ankle Society, Ankle-Hindfoot Score measure: 36-Item Short Form Survey sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: university clinical hospital № 1I.M.Sechenov First Moscow State Medical University. The Department of Traumatology, Orthopedics and Disaster Surgery status: RECRUITING city: Moscow zip: 119991 country: Russian Federation name: Marina M Lipina, MD, PhD role: CONTACT phone: +79253122096 email: marina.lipina@icloud.com lat: 55.75222 lon: 37.61556 hasResults: False
nctId: NCT06331728 id: IGNX-T1 briefTitle: Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001 overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2025-08 date: 2025-10 date: 2024-03-26 date: 2024-03-26 name: IgGenix Australia Pty Ltd class: INDUSTRY briefSummary: The goal of this randomized, double-blind, placebo-controlled, single ascending dose clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IGNX001 in peanut-allergic adults and older Adolescents. conditions: Peanut Allergy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized, double-blind, placebo-controlled, single ascending dose study with single blind sentinel period primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: With the exception of the single sentinel participants for each cohort who will be single blinded (participant blinded), the study will be designed as a double-blind study thus the Investigator, site staff (other than pharmacists), sponsor, sponsors delegates (if applicable) and participants are all blinded to treatment. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 24 type: ESTIMATED name: IGNX001 name: Placebo measure: Incidence and Severity of Treatment Emergent Adverse Events measure: Incidence of Serious Adverse Events and Suspected Unexpected Serious Adverse Reactions measure: Number of Participants with Clinically significant Changes from Baseline - Hematology measure: Number of Participants with Clinically Significant Changes from Baseline - Chemistry measure: Number of Participants with Clinically Significant Changes from Baseline - 12-lead ECGs for HR, PR, QRS, QT, RR and QTcF, and information on T- and U-waves measure: Number of Participants with Clinically Significant Changes from Baseline - Physical Examinations measure: Concentration of IGNX001 in the Plasma measure: Measurement of Area under the Plasma/Serum Concentration Curve (AUC) measure: Peak Serum Concentration (Cmax) measure: Time to Peak Serum Concentration (Tmax) measure: Elimination Half-life (t1/2) measure: Changes Over Time to Anti-drug Antibodies sex: ALL minimumAge: 15 Years maximumAge: 55 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06331715 id: ML1005 briefTitle: Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mg overallStatus: NOT_YET_RECRUITING date: 2024-05-06 date: 2024-08-01 date: 2024-08-31 date: 2024-03-26 date: 2024-03-26 name: Megalabs class: INDUSTRY briefSummary: An open label, balanced, randomized, two treatments, two sequences, two periods, cross over, single dose, bioequivalence study of Palbociclib 125 mg Capsules of Iclos Uruguay S.A and IBRANCE® (Palbociclib) 125 mg Capsules of Pfizer Europe (Belgium) in healthy, adult, human subjects under fed condition. conditions: Bioequivalence studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: OTHER masking: NONE count: 24 type: ESTIMATED name: Palbociclib 125mg measure: AUC 0-t measure: Cmax sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
nctId: NCT06331702 id: CDBJEIV2023001 briefTitle: Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR) overallStatus: RECRUITING date: 2024-03-02 date: 2024-09-30 date: 2024-12-31 date: 2024-03-26 date: 2024-03-26 name: Liaoning Chengda Biotechnology CO., LTD class: INDUSTRY briefSummary: This is a phase IV, randomized, controlled, open-label study proceed in healthy children aged 8 months in China. The primary objective is to demonstrate the immunogenicity of simultaneous administration of JEV-I and MMR is not inferior to that of separate administration, as measured by seroconversion rates and antibody titers against the four antigens. The secondary objective is to describe the safety of the vaccines when administered simultaneously or separately. conditions: Japanese Encephalitis conditions: Measles conditions: Mumps conditions: Rubella studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 396 type: ESTIMATED name: Vero cell-drived inactive Japanese encephalitis vaccine name: Measles-Mumps-Rubella Vaccine measure: Antibody Titer for Post Vaccination measure: Seroconversion Rate for Post Vaccination measure: Incidence of Any Local and Systemic Adverse Events Within 30 Minutes of Each Vaccination measure: Incidence of Solicited Local and Systemic Adverse Events Within 7 Days of Each Vaccination measure: Incidence of Unsolicited Adverse Events and Serious Adverse Events Within 30 Days of Post Vaccination sex: ALL minimumAge: 8 Months maximumAge: 12 Months stdAges: CHILD facility: Jiangsu Provincial Center for Disease Control and Prevention status: RECRUITING city: Nanjing state: Jiangsu zip: 210009 country: China name: Zhiguo Wang, Master role: CONTACT phone: +86 18118996978 email: 120714991@QQ.com name: Zhiguo Wang, Master role: PRINCIPAL_INVESTIGATOR lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06331689 id: HP-epidemıology briefTitle: EPIDEMIOLOGY AND ITS RESULTS IN HIP FRACTURES FOLLOWED IN POSTOPERATIVE INTENSIVE CARE acronym: Hip fractures overallStatus: COMPLETED date: 2021-02-01 date: 2021-04-01 date: 2021-07-01 date: 2024-03-26 date: 2024-03-26 name: Kutahya Health Sciences University class: OTHER briefSummary: Type of study: Observational study Goal of this : We conducted a retrospective evaluation of patients with HF who received postoperative ICU, with a focus on 30-day, 90-day and 1-year mortality outcomes.
Participant population/health conditions:Patients over the age of 18 who are hospitalized in the intensive care unit of our hospital after hip fracture operation. conditions: Hip Fracture conditions: Mortality Rate studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 68 type: ACTUAL measure: mortalite ratio sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kütahya Health Sciences University city: Kütahya zip: 43100 country: Turkey lat: 39.42417 lon: 29.98333 hasResults: False
nctId: NCT06331676 id: 69HCL23_1120 id: 2023-A02339-36 type: OTHER domain: ID RCB briefTitle: Developing a Complex ex Vivo Endometrial Tissue Model to Improve Endometriosis Care acronym: OTEndo overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-10 date: 2025-10 date: 2024-03-26 date: 2024-03-26 name: Hospices Civils de Lyon class: OTHER briefSummary: Endometriosis is a chronic gynaecological disease characterised by the growth of endometrium outside the uterus. It affects 10% of childbearing age women.
The aim of this project is to develop a complex ex vivo endometrial model recapitulating the organisation and properties of the human endometrium using innovative tissue bioengineering methods. This model will make it possible to develop a pre-clinical approach that predicts individual response to different types of hormonal treatment in order to optimise therapeutic choices and provide a better understanding of the effects of these treatments. conditions: Endometriosis studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants enrolled in this study will be given an eutopic and ectopic endometrium biopsies, blood and peritoneal fluid sampling and should answer to a questionnaire on menstrual health and history of hormone treatments for the research purpose.. primaryPurpose: BASIC_SCIENCE masking: NONE count: 45 type: ESTIMATED name: Tissue collection name: Data collection measure: Viability of all the cells forming the complex endometrial tissue generated ex vivo by tissue bioengineering. measure: Change in protein expression measure: Change in gene expression measure: Change in inflammation measure: Change in histological tissue structure measure: Change in histological tissue structure measure: Change in tissue elasticity measure: Change in steroid hormone physiology measure: Steroid hormones in peritoneal fluid sex: FEMALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Hôpital Femme Mère Enfant / GHE city: Bron zip: 69500 country: France name: Charles-André PHILIP, MD, PhD role: CONTACT phone: 04 27 85 51 70 phoneExt: +33 email: charles-andre.philip01@chu-lyon.fr lat: 45.73333 lon: 4.91667 facility: Hôpital de la Croix-Rousse / GHN city: Lyon zip: 69004 country: France name: Gil DUBERNARD, MD, PhD role: CONTACT phone: 04 72 07 16 42 phoneExt: +33 email: gil.dubernard@chu-lyon.fr lat: 45.74848 lon: 4.84669 hasResults: False
nctId: NCT06331663 id: KMUHIRB-F(II)-20240055 briefTitle: SPI and Remifentanil in Skull Pin Fixation overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-06-20 date: 2024-06-20 date: 2024-03-26 date: 2024-03-26 name: Kaohsiung Medical University Chung-Ho Memorial Hospital class: OTHER briefSummary: Forty patients were enrolled, and all patients used total intravenous anesthesia (remifentanil-propofol based total intravenous analgesia) as anesthesia induction and maintenance. According to the preliminary data of this department, patients who underwent intracranial surgery for skull pin fixation used remifentanil 5.0-6.0 ng/ml, while the hemodynamics is relatively stable. Therefore, when this plan is implemented, the patient needs to be under the same depth of anesthesia (monitored by electroencephalography, maintaining a value of 40-60), first start with remifentanil 5.0 ng/ml, and use the up and down method as adjust 0.5 ng/ml of concentration of remifentanil each time. Inadequate antinociception (Surgical Pleth Index(SPI) \> 80 and hyperdynamics (the increased heart rate (HR) and mean blood pressure (MBP) above 20% of baseline or HR\>100bpm and arterial blood pressure(ABP)\>180/100mmHg)) is defined as failure, therefore we increase remifentanil by 0.5 ng/ml; otherwise, the setting is considered successful without abovementioned situations.
Data collection: heart rate, mean blood pressure, Surgical Pleth Index, bispectral Index, pulse pressure variance, systolic pressure variance, concentrations of propofol and remifentanil before 2 mins, during, 5, and 15 mins of skull pin fixation were recorded and analyzed. conditions: Pain, Procedural studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 27 type: ESTIMATED name: Remifentanil measure: 50% effect concentration of remifentanil measure: 90% effect concentration of remifentanil sex: ALL minimumAge: 20 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kaohsiung Medical University Chung-Ho Memorial Hospital city: Kaohsiung country: Taiwan name: Zhi-Fu Wu, MD role: CONTACT phone: 07-3121101 phoneExt: 7035 email: aneswu@gmail.com lat: 22.61626 lon: 120.31333 hasResults: False